Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georgina V Long

Showing results (11-20 of 574) with videos related to

Pageof 58
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapiesGeorgina V Long, Kim A Margolin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2016
Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?Matteo S Carlino, Georgina V Long
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanomaAlexander M Menzies, Georgina V Long
Asia-Pacific Journal of Clinical Oncology|April 10, 2014
The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutationMichael P Brown, Georgina V Long
The Lancet. Oncology|April 1, 2017
Optimum dosing of ipilimumab in melanoma: too little, too late?Alexander M Menzies, Georgina V Long
Chinese Clinical Oncology|June 27, 2015
Systemic therapies for melanoma brain metastases: which drug for whom and when?Sangeetha Ramanujam, Dirk Schadendorf, Georgina V Long
The New England Journal of Medicine|April 4, 2019
Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. ReplyGeorgina V Long, Eduard Gasal, Axel Hauschild
The Lancet. Oncology|September 9, 2017
Primary medical therapy for BRAF<sup>V600E</sup>-mutant melanoma brain metastases-is this good enough? - Authors' replyMichael A Davies, Philippe Saiag, Georgina V Long
The New England Journal of Medicine|February 15, 2018
Adjuvant Therapy in Resected MelanomaGeorgina V Long, Axel Hauschild, John M Kirkwood
The Lancet. Oncology|January 2, 2013
Cutaneous toxicities of RAF inhibitorsRachael Anforth, Pablo Fernandez-Peñas, Georgina V Long
Pageof 58

Showing results (11-20 of 574) with videos related to

Sort By:
Pageof 58
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapiesGeorgina V Long, Kim A Margolin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2016
Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?Matteo S Carlino, Georgina V Long
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanomaAlexander M Menzies, Georgina V Long
Asia-Pacific Journal of Clinical Oncology|April 10, 2014
The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutationMichael P Brown, Georgina V Long
The Lancet. Oncology|April 1, 2017
Optimum dosing of ipilimumab in melanoma: too little, too late?Alexander M Menzies, Georgina V Long
Chinese Clinical Oncology|June 27, 2015
Systemic therapies for melanoma brain metastases: which drug for whom and when?Sangeetha Ramanujam, Dirk Schadendorf, Georgina V Long
The New England Journal of Medicine|April 4, 2019
Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. ReplyGeorgina V Long, Eduard Gasal, Axel Hauschild
The Lancet. Oncology|September 9, 2017
Primary medical therapy for BRAF<sup>V600E</sup>-mutant melanoma brain metastases-is this good enough? - Authors' replyMichael A Davies, Philippe Saiag, Georgina V Long
The New England Journal of Medicine|February 15, 2018
Adjuvant Therapy in Resected MelanomaGeorgina V Long, Axel Hauschild, John M Kirkwood
The Lancet. Oncology|January 2, 2013
Cutaneous toxicities of RAF inhibitorsRachael Anforth, Pablo Fernandez-Peñas, Georgina V Long
Pageof 58